Literature DB >> 28752789

Discrepancy analysis and Australian norms for the Trail Making Test.

Graeme Senior1, Adina Piovesana2, Patricia Beaumont3.   

Abstract

OBJECTIVE: Discrepancy analyses refer to comparison methods that evaluate the relationship or differences between two measures in the same individual. A common type of discrepancy analysis involves the comparison of two trials within a measure, such as, Trails A and B of the Trail Making Test (TMT). The TMT is well-suited to this role as the two measures are highly correlated, assess similar underlying constructs, and most importantly demonstrate differential vulnerability to the impact of pathology. While the inclusion of these types of data in the form of difference scores or ratios has become more frequent, this information has been presented only for demographically adjusted subgroups and has not taken into account the level of performance of the comparison trial, Trails A.
METHOD: The role and advantages of discrepancy analysis with the TMT stratified by level of Trails A performance were demonstrated with an Australian normative sample of 647 participants and a heterogeneous clinical sample consisting of 2,292 Australian and U.S.
RESULTS: The ability to differentiate between the influence of slowed visual scanning and/or graphomotor speed, and reduced mental flexibility was demonstrated by applying the normative data to clinical case discrepancies. The importance of accounting for the variability in discrepancy scores associated with the level of performance of Trails A was also highlighted.
CONCLUSION: A simple, efficient, and effective approach to examining the basis for differences between TMT-A and TMT-B performances is provided to examine the relative contributions of perceptual/motor abilities, and mental flexibility.

Entities:  

Keywords:  Discrepancy analysis; Trail Making Test; neuropsychology; norms

Mesh:

Year:  2017        PMID: 28752789     DOI: 10.1080/13854046.2017.1357756

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  6 in total

1.  Normative Data for Derived Measures and Discrepancy Scores for the Uniform Data Set 3.0 Neuropsychological Battery.

Authors:  Paulina V Devora; Samantha Beevers; Andrew M Kiselica; Jared F Benge
Journal:  Arch Clin Neuropsychol       Date:  2019-01-24       Impact factor: 2.813

2.  Higher levels of neuroticism in older adults predict lower executive functioning across time: the mediating role of perceived stress.

Authors:  Chloé Da Silva Coelho; Emilie Joly-Burra; Andreas Ihle; Nicola Ballhausen; Maximilian Haas; Alexandra Hering; Morgane Künzi; Gianvito Laera; Greta Mikneviciute; Doriana Tinello; Matthias Kliegel; Sascha Zuber
Journal:  Eur J Ageing       Date:  2021-12-16

3.  Quantitative and qualitative features of executive dysfunction in frontotemporal and Alzheimer's dementia.

Authors:  Andrew M Kiselica; Jared F Benge
Journal:  Appl Neuropsychol Adult       Date:  2019-08-19       Impact factor: 2.248

4.  Young-Old City-Dwellers Outperform Village Counterparts in Attention and Verbal Control Tasks.

Authors:  Hana Stepankova Georgi; Zuzana Frydrychova; Karolina Horakova Vlckova; Lucie Vidovicova; Zdenek Sulc; Jiri Lukavsky
Journal:  Front Psychol       Date:  2019-05-28

5.  Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study.

Authors:  Helen Vidot; Erin Cvejic; Liam J Finegan; E Arthur Shores; David G Bowen; Simone I Strasser; Geoffrey W McCaughan; Sharon Carey; Margaret Allman-Farinelli; Nicholas A Shackel
Journal:  Nutrients       Date:  2019-08-06       Impact factor: 5.717

6.  Psychotropic Polypharmacy in Adults 55 Years or Older: A Risk for Impaired Global Cognition, Executive Function, and Mobility.

Authors:  Gilles Loggia; Elpidio Attoh-Mensah; Kristell Pothier; Rémy Morello; Pascale Lescure; Marie-Laure Bocca; Christian Marcelli; Chantal Chavoix
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.